AI-Enhanced Remote Patient Intravenous (IV) Monitoring Market Report 2026

The artificial intelligence (AI)-enhanced remote patient intravenous (iv) monitoring market size has grown exponentially in recent years. It will grow from $1.69 billion in 2025 to $2.05 billion in 2026 at a compound annual growth rate (CAGR) of 21.6%. The growth in the historic period can be attributed to increasing use of intravenous therapies in clinical care, rising incidence of infusion-related complications, expansion of hospital patient monitoring systems, growing adoption of smart infusion devices, increased focus on medication safety protocols.

The artificial intelligence (AI)-enhanced remote patient intravenous (iv) monitoring market size is expected to see exponential growth in the next few years. It will grow to $4.45 billion in 2030 at a compound annual growth rate (CAGR) of 21.3%. The growth in the forecast period can be attributed to increasing adoption of ai-enabled infusion monitoring, rising demand for home-based iv therapy solutions, expansion of predictive patient safety analytics, growing integration of connected infusion systems, increasing emphasis on remote clinical monitoring. Major trends in the forecast period include increasing adoption of real-time iv flow analytics, rising use of AI-based infusion error detection, growing integration of smart infusion sensors, expansion of remote iv therapy management, enhanced focus on patient safety and compliance.

The expansion of telehealth services is expected to drive the growth of the artificial intelligence (AI)-enhanced remote patient intravenous (IV) monitoring market in the coming years. Telehealth services deliver healthcare through digital communication technologies, allowing medical consultations, monitoring, and treatment to be conducted remotely. Telehealth adoption has increased due to regulatory changes and reimbursement policies introduced during the COVID-19 pandemic, making virtual healthcare more accessible and cost-effective for both providers and patients. AI-enhanced remote patient IV monitoring supports telehealth by enabling real-time tracking of patients’ IV therapy, automatically detecting complications, providing actionable insights to healthcare providers, and integrating seamlessly with virtual care platforms to ensure timely interventions, improved patient safety, and efficient management of home-based and outpatient treatments. For example, in April 2023, FAIR Health Inc., a US-based non-profit organization, reported that national telehealth use increased by 7.3%, rising from 5.5% of medical claim lines in December 2022 to 5.9% in January 2023. Consequently, the expansion of telehealth services is fueling the growth of the AI-enhanced remote patient IV monitoring market.

The proliferation of wearable health technologies is also expected to drive the growth of the AI-enhanced remote patient IV monitoring market. Wearable health technologies, such as smartwatches and fitness trackers, monitor various health metrics in real time. Their adoption is increasing due to rising health awareness, as more people track vital signs and seek tools that provide instant insights into their well-being. Wearable technologies support remote patient IV monitoring by continuously collecting real-time physiological data, which can be analyzed to detect anomalies, optimize IV treatment, and enable timely, personalized interventions without requiring constant in-person supervision. For instance, in April 2025, the UK Parliament's House of Commons Library reported that between 2023 and 2024, the NIHR and UKRI invested approximately USD 15 million (£11.5 million) in 10 research projects aimed at developing wearable technologies to support greater independence for people living with frailty or long-term physical disabilities. Therefore, the proliferation of wearable health technologies is driving the growth of the AI-enhanced remote patient IV monitoring market.

Increasing healthcare expenditure is also expected to propel the growth of the AI-enhanced remote patient IV monitoring market. Healthcare expenditure refers to the total financial resources spent on healthcare services and products within a given period. This spending is rising due to growing demand for advanced medical technologies and services to improve patient outcomes, enhance treatment efficiency, and support the adoption of AI-enhanced remote patient monitoring. Higher healthcare expenditure supports AI-enhanced remote patient IV monitoring by funding advanced technologies, digital infrastructure, and staff training for more efficient and accurate patient care. For example, in June 2025, the Centers for Medicare & Medicaid Services, a US-based government agency, reported that in 2023, national health expenditures (NHE) increased by 7.5% to reach $4.9 trillion, averaging $14,570 per person and representing 17.6% of GDP. Medicare spending rose by 8.1% to $1.02 trillion, accounting for 21% of total NHE. Consequently, increasing healthcare expenditure is fueling the growth of the AI-enhanced remote patient IV monitoring market.

Major companies operating in the artificial intelligence (AI)-enhanced remote patient intravenous (iv) monitoring market are Medtronic plc, Siemens Healthineers AG, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Baxter International Inc., B. Braun Melsungen AG, Terumo Corporation, Nipro Corporation, Epic Systems Corporation, ICU Medical Inc., InfuSystem Holdings Inc., AlayaCare Inc., Huma Therapeutics Ltd., Health Recovery Solutions Inc., Arcomed AG, VitalConnect Inc., Cloud DX Inc., Empatica S.r.l., AccuHealth Inc., Serum Tracker Inc.

North America was the largest region in the artificial intelligence (AI)-enhanced remote patient intravenous (IV) monitoring market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI)-enhanced remote patient intravenous (iv) monitoring market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence (AI)-enhanced remote patient intravenous (iv) monitoring market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the AI-enhanced remote patient intravenous monitoring market by increasing costs of imported infusion sensors, monitoring hardware, communication modules, and analytics infrastructure. Hospitals and clinics in North America and Europe are most affected due to reliance on imported smart infusion technologies, while Asia-Pacific faces higher manufacturing and export costs. These tariffs are increasing system deployment costs and slowing adoption in ambulatory and homecare settings. However, they are also encouraging regional device manufacturing, localized software development, and investment in domestically produced IV monitoring solutions.

The artificial intelligence (AI)-enhanced remote patient intravenous (iv) monitoring market research report is one of a series of new reports that provides artificial intelligence (AI)-enhanced remote patient intravenous (iv) monitoring market statistics, including artificial intelligence (AI)-enhanced remote patient intravenous (iv) monitoring industry global market size, regional shares, competitors with a artificial intelligence (AI)-enhanced remote patient intravenous (iv) monitoring market share, detailed artificial intelligence (AI)-enhanced remote patient intravenous (iv) monitoring market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI)-enhanced remote patient intravenous (iv) monitoring industry. This artificial intelligence (AI)-enhanced remote patient intravenous (iv) monitoring market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Artificial intelligence (AI)-enhanced remote patient intravenous (IV) monitoring is a system that uses AI algorithms to continuously track and analyze IV therapy data in real time. It detects irregularities, predicts complications, and optimizes fluid or medication delivery based on patient-specific patterns. The technology combines sensors, data analytics, and automated alerts to enhance safety and efficiency in IV therapy management.

The main components of AI-enhanced remote patient IV monitoring include hardware, software, and services. Hardware comprises the physical devices that collect and process data, such as infusion pumps and wearable patient monitors. These systems are deployed through on-premises or cloud-based models. Applications include hospitals, clinics, homecare settings, ambulatory surgical centers, and more, serving end-users such as healthcare providers and patients.

The artificial intelligence (AI)-enhanced remote patient intravenous (IV) monitoring market consists of revenues earned by entities by providing services such as continuous IV flow monitoring, AI-powered predictive analytics, remote patient monitoring, automated alerts and notifications, data management and reporting, telehealth integration, device management and support, and medication management support. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence (AI)-enhanced remote patient intravenous (IV) monitoring market also includes sales of flow meters, pressure transducers, wireless control interfaces for infusion pumps, cloud-integrated drug infusion systems, and AI-enhanced remote monitoring platforms. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.